公开(公告)号：US12043673B2

公开(公告)日：2024-07-23

申请号：US17503132

申请日：2021-10-15

Applicant: City of Hope

Inventor： John E. Shively ,  Lin Li ,  Maciej Kujawski ,  Piotr Swiderski

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/42 ,  C07K16/46 ,  C07K19/00

CPC classification number: C07K16/4283 ,  C07K16/283 ,  C07K16/2878 ,  C07K16/46 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52

Abstract: The compositions and methods provide herein include, inter alia, antibodies attached to single-stranded oligoribonucleotides. Two antibodies are capable of forming complexes in vivo through hybridization of the respective complementary oligoribonucleotides they are bound to. For example, a first antibody bound to a first oligoribonucleotide through a first chemical linker may be administered to a subject, bind to a cell surface antigen in vivo and subsequently form an antibody complex in vivo with a second antibody bound to a second oligoribonucleotide through a second chemical linker, through complementary base-pairing between the first and the second oligoribonucleotide. The compositions and methods provided herein are, inter alia, useful for diagnostic and therapeutic purposes, for example, the treatment of cancer or autoimmune disease.

公开(公告)号：US20230256122A1

公开(公告)日：2023-08-17

申请号：US18145614

申请日：2022-12-22

Applicant: City of Hope

Inventor： John E. Shively ,  Maciej Kujawski ,  Megan Minnix ,  Paul Yazaki

IPC: A61K51/10 ,  A61K47/68 ,  A61P35/00

CPC classification number: A61K51/1048 ,  A61K51/1096 ,  A61K47/6853 ,  A61K47/6813 ,  A61P35/00

Abstract: Provided herein, inter alia, are radionuclide-labeled antibodies, immunocytokines, and methods for treating cancer using combination therapy with the radionuclide-labeled antibodies and the immunocytokines.

公开(公告)号：US20230190799A1

公开(公告)日：2023-06-22

申请号：US17870024

申请日：2022-07-21

Applicant: City of Hope

Inventor： John E. Shively ,  Maciej Kujawski ,  Seung E. Cha ,  Paul Yazaki

IPC: A61K35/17 ,  C07K16/30 ,  A61K31/664 ,  A61P35/00 ,  A61P1/00 ,  A61K38/20 ,  A61K38/17 ,  A61K39/395

CPC classification number: A61K35/17 ,  C07K16/3007 ,  A61K31/664 ,  A61P35/00 ,  A61P1/00 ,  A61K38/2013 ,  A61K38/1774 ,  A61K39/39558 ,  C07K2317/622 ,  C07K2317/55 ,  A61K2039/545

Abstract: Aspects of the present disclosure provide methods for treating a subject having a carcinoembryonic antigen (CEA)-positive tumor using a conditioning regimen (lymphodepleting treatment), which comprises administering one or more doses of a lymphodepleting agent to a subject, and a treatment regimen, which comprises administrating one or more doses of the anti-CEA CAR T cells and/or the ICK proteins to the subject.

公开(公告)号：US20220119552A1

公开(公告)日：2022-04-21

申请号：US17503132

申请日：2021-10-15

Applicant: City of Hope

Inventor： John E. Shively ,  Lin Li ,  Maciej Kujawski ,  Piotr Swiderski

IPC: C07K16/42 ,  C07K16/28 ,  C07K16/46

Abstract: The compositions and methods provide herein include, inter alia, antibodies attached to single-stranded oligoribonucleotides. Two antibodies are capable of forming complexes in vivo through hybridization of the respective complementary oligoribonucleotides they are bound to. For example, a first antibody bound to a first oligoribonucleotide through a first chemical linker may be administered to a subject, bind to a cell surface antigen in vivo and subsequently form an antibody complex in vivo with a second antibody bound to a second oligoribonucleotide through a second chemical linker, through complementary base-pairing between the first and the second oligoribonucleotide. The compositions and methods provided herein are, inter alia, useful for diagnostic and therapeutic purposes, for example, the treatment of cancer or autoimmune disease.